Ampersand makes offer for AcCell product line:
This article was originally published in Clinica
Ampersand Medical has offered to buy AccuMed International's AcCell product line, including intellectual property and AccuMed's contracted customer base, for cash, royalties and a licence back for certain AccuMed technology. The AcCell system is a range of automated computer-assisted microscopy work-stations and software that are integrated with lab information systems for the screening and diagnosis of cervical Pap smears and cytology specimens. Chicago-based Ampersand wishes to integrate aspects of the system into its bio-molecular diagnostic systems.
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.